Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The
discovery of several oncogenic driver mutations in patients with NSCLC has allowed the …

Purpose In non–small-cell lung cancer (NSCLC), the epidermal growth factor receptor
(EGFR) and cyclooxygenase-2 (COX-2) play major roles in tumorigenesis. This phase I/II …

Abstract Introduction/Background Given the limited gains of traditional chemotherapy in
improving outcomes in patients with advanced non–small-cell lung cancer (NSCLC), recent …

We performed a meta-analysis of fatal pulmonary events associated with erlotinib, gefitinib
or afatinib in patients with non-small-cell lung cancer (NSCLC). Eligible studies included …

Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …

Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Abstract Background In Non-small cell lung cancer (NSCLC), an overactive epidermal
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …

9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …

Among treatment modalities for lung cancer, the most promising therapy is the use of
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and …